Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 ...Middle East

-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir,...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 )

Also on site :

• Final Palisades fire evacuation order lifted
• 'Unprecedented' number of US Air Force aerial refueling tankers heading toward Europe
• Walmart Is Selling a ‘Lightweight’ $116 Cordless Vacuum for Just $60, and Shoppers Say It’s 'Easy to Move and Carry'